GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Editas Medicine Inc.
Editas Medicine is a pioneer in CRISPR gene editing. Its stock price represents a venture capital bet on the revolutionary potential of this technology. The chart reflects high volatility associated with news of clinical trial progress.
Share prices of companies in the market segment - Dna
Editas Medicine (EDIT) is a leading gene editing company developing CRISPR-based therapeutics for a wide range of genetic diseases. We classify it as a "DNA technology." The chart below illustrates the dynamics of this revolutionary biotech sector.
Broad Market Index - GURU.Markets
Editas Medicine is a leading CRISPR gene editing company developing drugs to treat genetic diseases. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. See how Editas is outperforming the overall market.
Change in the price of a company, segment, and market as a whole per day
EDIT - Daily change in the company's share price Editas Medicine Inc.
The volatility of Editas, a pioneer in CRISPR genome editing, reflects the promise and risks of this technology. Change_co measures extreme sensitivity to clinical trial news. This parameter is important for formulas on System.GURU.Markets that analyze companies at the forefront of science.
Daily change in the price of a set of shares in a market segment - Dna
Editas Medicine, Inc. is a pioneer in CRISPR gene editing. This chart illustrates the extreme volatility of the biotech sector. Comparing it to EDIT, which is a near-pure bet on the success of this revolutionary technology, clearly demonstrates its extreme risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Editas is a pioneering company in the field of CRISPR gene editing, one of the most cutting-edge and speculative areas in biotech. The chart below illustrates the extreme volatility typical of this sector, reflecting the enormous expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Editas Medicine Inc.
The year-over-year performance of Editas Medicine, a pioneer in CRISPR gene editing technology, is a story of the transition from scientific idea to clinical practice. Its 12-month market capitalization is crucially dependent on the data from its first clinical trials. Success could confirm the enormous potential of the entire platform, while failure could set it back for years.
Annual dynamics of market capitalization of the market segment - Dna
Editas Medicine, Inc. is a leading company developing drugs based on the revolutionary CRISPR gene-editing technology. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential and high risks of this cutting-edge field of biotechnology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Editas, a pioneer in the revolutionary CRISPR gene editing technology, is a bet on the technology of the future. Its stock price is completely unrelated to the economy. Its chart reflects the hopes, risks, and scientific breakthroughs in one of the most advanced fields of medicine. It's a long-term bet on a technology that could change the world.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Editas Medicine Inc.
The valuation of Editas, a pioneer in CRISPR gene editing, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of its gene therapy clinical trials, the success of which determines whether this revolutionary technology will truly realize its potential.
Monthly dynamics of market capitalization of the market segment - Dna
Editas Medicine is one of the leading companies using CRISPR gene editing technology to develop drugs for severe genetic diseases. Its market capitalization is a bet on revolutionizing medicine. The chart below reflects the general sentiment in the cutting-edge genetic engineering sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Editas Medicine, Inc. is a leading company in the field of CRISPR gene editing. Its stock represents a long-term bet on a revolution in medicine. Its performance is completely unrelated to the market and is driven by scientific breakthroughs, partnership news, and preclinical and clinical trial results.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Editas Medicine Inc.
Shares of Editas Medicine, a pioneer in CRISPR genome editing, are extremely volatile. Weekly price movements reflect any news about progress in clinical trials, scientific publications, and patent disputes in this cutting-edge field. The chart below illustrates how short-term scientific events can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Dna
How unique is Editas Medicine's performance in the biotech sector? This chart compares the weekly stock price movements of the CRISPR genome editing pioneer with the overall trend. This helps us understand whether its sharp movements are a unique reaction to news in this cutting-edge field or reflect the broader sentiment of the volatile sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Editas Medicine is a leading company in the field of CRISPR genome editing. It's a revolutionary but risky technology. This chart compares its volatile weekly performance to the market, showing how its stock moves based on news about scientific breakthroughs, completely ignoring overall market trends.
Market capitalization of the company, segment and market as a whole
EDIT - Market capitalization of the company Editas Medicine Inc.
The valuation of Editas Medicine, Inc. on the chart reflects the enormous potential and risks of CRISPR gene editing technology. The market capitalization of one of the pioneers in this field depends on the success of its first clinical trials. The dynamics vividly illustrate how investors value this revolutionary, yet commercially unproven, science.
EDIT - Share of the company's market capitalization Editas Medicine Inc. within the market segment - Dna
Editas Medicine, Inc. is a pioneer in the field of CRISPR gene editing. Its market share reflects its status as one of the first companies in this revolutionary field. Its market capitalization reflects its technological platform and clinical programs.
Market capitalization of the market segment - Dna
Take a look at the chart: it's the total market capitalization of the revolutionary CRISPR gene editing industry. Editas Medicine is one of the founders and key players. The dynamics on the chart reflect the enormous hopes, scientific breakthroughs, and ethical controversies surrounding this futuristic technology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's the market valuation of one of the most advanced technologies of the 21st century—genome editing. Editas Medicine's market cap is a bet on its CRISPR platform for treating genetic diseases. The chart shows how the promise of DNA "correction" is shaping its enormous potential share in the future of global medicine.
Book value capitalization of the company, segment and market as a whole
EDIT - Book value capitalization of the company Editas Medicine Inc.
The graph below shows the scientific foundation of Editas Medicine. Its line reflects the value of the intellectual property for the CRISPR gene editing platform, as well as the cash reserves for clinical trials. An increase in the graph indicates progress in developing breakthrough treatments for genetic diseases.
EDIT - Share of the company's book capitalization Editas Medicine Inc. within the market segment - Dna
Editas Medicine's tangible assets include its cutting-edge laboratories and CRISPR gene editing equipment. The chart shows the company's share of this unique and capital-intensive scientific infrastructure, which forms the physical foundation for developing breakthrough treatments for genetic diseases.
Market segment balance sheet capitalization - Dna
Below you can see the overall book value of the biotech sector. Against this backdrop, Editas Medicine, a pioneer in CRISPR genome editing, looks like a lightweight. Its capital isn't in its factories, but in some of the most valuable intellectual property in science. Its balance sheet is modest compared to its scientific potential.
Book value of all companies included in the broad market index - GURU.Markets
Editas Medicine is a pioneer in the field of CRISPR genome editing. The company's assets are not drugs, but rather fundamental patents on the technology and a portfolio of research programs. Their balance sheet represents the value of the "molecular scissors" that could one day correct genetic errors in biology, the foundation of the entire real world.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Editas Medicine Inc.
Editas's balance sheet is defined by its massive cash reserves and fundamental CRISPR patents. Its market cap, close to its price, shows the market's disillusionment with its ability to turn its revolutionary technology into drugs. MvsBCap_Co's chart here is a story of how a "dream" is worth next to nothing without results.
Market to book capitalization ratio in a market segment - Dna
Editas Medicine is a leading company in the field of CRISPR gene editing. Its value lies in its revolutionary technology. The chart shows the enormous premium the market places on its scientific potential to transform medicine, which far exceeds the value of its laboratories and equipment.
Market to book capitalization ratio for the market as a whole
Editas Medicine is a leading genome editing company using CRISPR technology to develop drugs for genetic diseases. Its greatest asset is the potential of its revolutionary technology. This chart clearly demonstrates why companies promising to transform medicine can command enormous market valuations even without profits.
Debts of the company, segment and market as a whole
EDIT - Company debts Editas Medicine Inc.
Editas Medicine, a pioneer in CRISPR gene editing, is using debt to fund groundbreaking research. This chart shows how the company is raising massive amounts of capital to develop treatments for genetic diseases. In this disruptive yet capital-intensive field, debt is an investment in technology that has the potential to transform medicine.
Market segment debts - Dna
Editas Medicine is a leading CRISPR genome editing company developing drugs to treat severe genetic diseases. This is one of the most cutting-edge and capital-intensive fields in science. This chart shows how the company funds its breakthrough, yet extremely expensive, research that could change medicine.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Editas Medicine Inc.
Editas Medicine is a leading company in the field of CRISPR gene editing. The chart shows how it funds its cutting-edge, yet extremely expensive, research. For a pioneer in such a revolutionary field, debt is a way to accelerate scientific progress, but it carries enormous risk if the technology encounters unforeseen scientific or regulatory hurdles.
Market segment debt to market segment book capitalization - Dna
Editas Medicine is a leading CRISPR genome editing company developing treatments for genetic diseases. This is a breakthrough, but extremely expensive, technology. The chart shows how the debt load of this company, funding the future of medicine, compares to the market capitalization of the entire biotech sector.
Debt to book value of all companies in the market
#VALUE!
P/E of the company, segment and market as a whole
P/E - Editas Medicine Inc.
This chart for Editas Medicine, a pioneering company in CRISPR genome editing, is a measure of faith in this revolutionary technology. There is no P/E ratio. The company's valuation is based not on revenue, but on the potential of its platform to create drugs for genetic diseases. The chart reflects progress in its clinical programs.
P/E of the market segment - Dna
Here's the average P/E for genome editing companies. For Editas Medicine, a CRISPR pioneer, it serves as a benchmark. This metric reflects the overall level of investor faith in this revolutionary technology, providing context for Editas's valuation, which is a bet on its specific clinical programs.
P/E of the market as a whole
Editas Medicine is a leading genome editing company developing drugs using CRISPR technology. The company aims to treat severe genetic diseases by correcting defective genes. This risk appetite chart helps understand how the market values breakthrough, yet early-stage, biotechnologies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Editas Medicine Inc.
Editas Medicine is a leading company developing therapeutics based on the revolutionary CRISPR gene editing technology. This graph reflects expectations for the future of gene medicine. The estimate is highly speculative and depends entirely on success in clinical trials and the ability to translate scientific breakthroughs into real-world treatments.
%20P%2FE%20Editas%20Medicine%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Editas-Medicine-Inc.&v=1772695662095 "Chart of the company's future (projected) P/E Editas Medicine Inc.")
Future (projected) P/E of the market segment - Dna
Editas Medicine is a leading gene editing company using CRISPR technology. This chart reflects the company's long-term profitability expectations compared to other biotech companies. It shows how highly the market values its potential to create breakthrough treatments for genetic diseases and cancer.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772695662121 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Editas Medicine is a leading CRISPR gene editing company. Its goal is to create cures for genetic diseases. This market expectations chart reflects the overall risk appetite in biotechnology. Market optimism makes it easier for Editas to raise the massive capital needed to bring its revolutionary technologies to market.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772695662133 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Editas Medicine Inc.
Editas Medicine is a leading genome editing company using CRISPR technology. It develops drugs to treat genetic diseases by correcting defective genes. Its financial performance reflects its massive investment in cutting-edge science. This chart shows the long and risky path to creating the medicine of the future.
Profit of companies in the market segment - Dna
Editas Medicine is a leading company in the field of CRISPR genome editing. Its goal is to create cures for genetic diseases. Its financial performance reflects its massive investment in cutting-edge science. This chart shows how the gene therapy sector is shaping the future of medicine, where current losses are a bet on technological revolution and future profitability.
Overall market profit
Editas Medicine is a leading CRISPR gene editing company. It aims to create cures for genetic diseases. This is the technology of the future, and Editas's success depends on scientific breakthroughs and clinical trial results. Its business operates outside the traditional economic cycles reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Editas Medicine Inc.
Editas Medicine is a leading gene editing company using CRISPR technology to create new drugs. This chart shows future revenue expectations, which are speculative at this stage. These projections depend entirely on the success of its clinical programs and the potential of this technology to treat genetic diseases.
%20profit%20of%20the%20company%20Editas%20Medicine%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Editas-Medicine-Inc.&v=1772695662256 "Graph of future (projected) profit of the company Editas Medicine Inc.")
Future (predicted) profit of companies in the market segment - Dna
Editas Medicine is a leading gene editing company using CRISPR technology to develop drugs for genetic diseases. This chart shows the revenue forecast for the entire DNA therapeutics industry. It reflects the high but long-term expectations for the revolutionary CRISPR technology. This backdrop is important for assessing Editas's scientific progress and potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772695662270 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Editas Medicine is a leading company in the field of CRISPR genome editing. Its future depends on scientific breakthroughs and the ability to translate this technology into drugs. The economic backdrop shown here influences the level of public and private investment in cutting-edge science, which underpins the entire gene therapy industry.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772695662274 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Editas Medicine Inc.
Editas Medicine is a leading genome editing company using CRISPR technology to create drugs for genetic diseases. This chart shows how investors value its revolutionary scientific platform. The valuation is based not on current revenue, but on the belief in future medical breakthroughs.
P/S market segment - Dna
Editas Medicine is a leading gene editing company developing therapeutics based on CRISPR technology. The company aims to treat severe diseases by precisely editing genes directly in the body. This chart shows the average valuation in the sector, helping to understand the market premium placed on this revolutionary scientific platform.
P/S of the market as a whole
Editas Medicine is a leading gene editing company using CRISPR technology to develop drugs for genetic diseases. This cutting-edge technology offers enormous potential and significant risks. This market valuation chart helps us understand the premium investors are paying for this potentially revolutionary, yet unrealized, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Editas Medicine Inc.
Editas Medicine is a leading company in the field of CRISPR genome editing. Being in the clinical stage, it is valued based on its future potential. This chart reflects investor expectations that its technology will lead to the creation of revolutionary drugs capable of generating huge revenues.
%20P%2FS%20Editas%20Medicine%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Editas-Medicine-Inc.&v=1772695662419 "The graph of the company's future (projected) P/S Editas Medicine Inc.")
Future (projected) P/S of the market segment - Dna
Editas Medicine is a leading company developing CRISPR-based genomic therapies. This chart compares market expectations for its future revenue with other companies in the DNA technology sector. The valuation reflects investor expectations for its breakthrough platform for treating genetic diseases.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772695662420 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Editas Medicine is a leading company in the field of CRISPR gene editing. It's betting on a technology that could revolutionize medicine. The market optimism, visible in this chart, reflects investors' faith in such breakthrough technologies. Editas needs this faith (and capital) to turn science fiction into real-world cures.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772695662433 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Editas Medicine Inc.
Editas Medicine is a leading company developing gene editing using CRISPR technology. Currently in clinical development, its revenue is generated through collaborations with major pharmaceutical companies to develop new drugs. The chart shows the financial flows from these partnerships, which fuel its cutting-edge research.
Sales of companies in the market segment - Dna
Editas Medicine is a leading gene editing company using CRISPR technology. It develops therapeutic drugs for the treatment of rare genetic diseases by directly correcting defective genes in the body. Currently, there is no revenue. This chart reflects the enormous potential and investment interest in gene therapy, which has the potential to transform medicine.
Overall market sales
Editas Medicine is a leading company in the field of CRISPR gene editing. This is the technology of the future, and the company's success depends on scientific breakthroughs and clinical trial results. This timeline is important indirectly, as it influences investor risk appetite and their willingness to fund revolutionary yet long-term scientific projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Editas Medicine Inc.
Editas Medicine is a leading company in the field of CRISPR genome editing. It develops treatments for genetic diseases by "correcting" DNA. This graph reflects analysts' confidence in Editas's technology platform and its ability to commercialize its therapeutic programs, a long-term prospect.
%20sales%20of%20the%20company%20Editas%20Medicine%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Editas-Medicine-Inc.&v=1772695662544 "Schedule of future (projected) sales of the company Editas Medicine Inc.")
Future (projected) sales of companies in the market segment - Dna
Editas Medicine is a leading company developing gene therapy using CRISPR genome editing technology. This chart shows the overall outlook for the DNA research sector. It allows one to assess the company's progress in clinical trials and whether its cutting-edge, yet complex, technology will lead to the development of revolutionary drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772695662641 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Editas Medicine is a leading company in the field of CRISPR gene editing. This chart, reflecting the investment climate in biotech, is critically important. Developing such a revolutionary technology requires massive and long-term investment, and Editas's ability to raise capital is directly dependent on investor confidence in the future success of gene therapy.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772695662720 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Editas Medicine Inc.
Editas Medicine is a leading CRISPR gene editing company developing transformative treatments for genetic diseases. Its business is groundbreaking science, requiring enormous investment. This chart illustrates the cost of innovation, showing the expenditure on research that can lead to medical breakthroughs.
Market segment marginality - Dna
Editas Medicine is one of the leading companies working with CRISPR gene editing technology. They are developing drugs to treat severe genetic diseases. Profitability is not their current goal; this chart reflects the intensity of their investment in a scientific platform that has the potential to revolutionize medicine and generate enormous profits in the future.
Market marginality as a whole
Editas Medicine is one of the leading companies in the field of CRISPR gene editing. Overall profitability is irrelevant to them. Their future lies at the cutting edge of science. Success depends on whether their technology can safely and effectively treat genetic diseases, potentially revolutionizing medicine.
Employees in the company, segment and market as a whole
Number of employees in the company Editas Medicine Inc.
Editas Medicine is a leading CRISPR gene editing company focused on developing treatments for genetic diseases. This chart shows its large team of scientists. The scale of its staff reflects the enormous investment required to transform this revolutionary scientific technology into real-world treatments.
Share of the company's employees Editas Medicine Inc. within the market segment - Dna
Editas Medicine is a leading company developing genomic drugs based on CRISPR technology. This chart shows the proportion of elite scientists in the field of genetic engineering that the company attracts. It illustrates its role as a pioneer in treating severe diseases through DNA editing and the scale of its research team.
Number of employees in the market segment - Dna
Editas Medicine is a leading genome editing company using CRISPR technology to create drugs for genetic diseases. This chart shows the growth of employment in this cutting-edge field of biotechnology. The increase in scientists reflects progress in clinical trials and the enormous potential of this technology to revolutionize medicine.
Number of employees in the market as a whole
Editas Medicine is a leading genome editing company, using CRISPR technology to create drugs for genetic diseases. It's the future of medicine. This chart, which illustrates the overall labor market, shows companies like Editas at the forefront of innovation, driving demand for exceptional specialists in genetics, molecular biology, and bioinformatics.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Editas Medicine Inc. (EDIT)
Editas Medicine, Inc. is a leading company in the field of CRISPR genome editing. Its value lies in the potential of its revolutionary technology. This chart clearly demonstrates a business built on intellectual capital. A small team of scientists can create a platform worth billions of dollars, resulting in an extremely high market capitalization per employee.
%20of%20the%20company%20Editas%20Medicine%20Inc.%20(EDIT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Editas-Medicine-Inc.-EDIT&v=1772695663242 "Chart of market capitalization per employee (in thousands of dollars) of the company Editas Medicine Inc. (EDIT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Editas Medicine is a leading company in the field of CRISPR genome editing. Its valuation is a bet on a future revolution in medicine. The chart clearly demonstrates the colossal premium investors place on intellectual capital, assessing the potential contribution of each employee to the creation of next-generation, life-changing drugs.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772695663276 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Editas Medicine is a leading company using CRISPR gene editing technology to create drugs for genetic diseases. This chart shows a very high market value per employee, reflecting not current revenue but the enormous potential of their revolutionary scientific platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772695663294 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Editas Medicine Inc. (EDIT)
Editas Medicine (EDIT) is one of the leading companies in the field of CRISPR genome editing. This is cutting-edge science. This chart shows the enormous R&D costs (negative profit) per scientist. This represents a net investment in a technology that has the potential to cure genetic diseases, but which currently requires enormous investment.
%20Chart%20Editas%20Medicine%20Inc.%20(EDIT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Editas-Medicine-Inc.-EDIT&v=1772695663299 "Company Profit Per Employee (in thousands of dollars) Chart Editas Medicine Inc. (EDIT)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Editas Medicine is a leading company in the field of CRISPR genome editing. They develop drugs to treat severe genetic diseases by "correcting" DNA. This graph demonstrates the benchmark performance of their biotech staff. It is important for assessing how effectively Editas' elite team of scientists is using this breakthrough technology.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772695663302 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Editas Medicine is a leading gene editing company using CRISPR technology. They strive to create cures for genetic diseases. They are at the cutting edge of science. The chart reflects the enormous investment (negative return) per employee required to fund research and clinical trials that could transform medicine.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772695663329 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Editas Medicine Inc. (EDIT)
Editas Medicine is one of the leading companies in the field of CRISPR genome editing. This chart demonstrates its status as a pioneer in this emerging field. Almost all of its activities are devoted to research and development. Zero revenue per employee is the norm for a company creating a platform that could transform medicine in the future but does not yet have commercial products.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Editas-Medicine-Inc.-EDIT&v=1772695663358 "Sales chart per company employee Editas Medicine Inc. (EDIT)")
Sales per employee in the market segment - Dna
Editas Medicine (EDIT) is a leading biotech company specializing in CRISPR gene editing. They are developing treatments for genetic diseases. This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their cutting-edge gene therapy R&D platform.
Sales per employee for the market as a whole
Editas Medicine is a leading company in the field of CRISPR gene editing. They use this revolutionary technology to create drugs. They are a clinical-stage R&D company with no commercial revenue. This graph (close to zero) shows how the company invests in its staff of highly qualified scientists working on technologies that could transform medicine.
Short shares by company, segment and market as a whole
Shares shorted by company Editas Medicine Inc. (EDIT)
Editas Medicine is a leading company in the field of genome editing (CRISPR). They are trying to treat genetic diseases. This chart shows bearish bets. The shorts are driven by the enormous risks of the technology: safety issues (off-target mutations), patent disputes, and doubts that their therapy will ever become widespread and profitable.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Editas-Medicine-Inc.-EDIT&v=1772695663452 "Short Shares Chart for the Company Editas Medicine Inc. (EDIT)")
Shares shorted by market segment - Dna
Editas Medicine (EDIT) is a biotech company, a pioneer in CRISPR gene editing, seeking to develop treatments for genetic diseases. This chart shows the odds against the entire gene therapy sector. The rising odds against the industry reflect deep investor skepticism about the safety, efficacy, and commercial viability of CRISPR technologies.
Shares shorted by the overall market
Editas Medicine (EDIT) is a pioneer in CRISPR gene editing. It's one of the most revolutionary, yet also most speculative, areas of biotech. This chart of general fear shows investors fleeing "science projects." For EDIT, which has no profit, market panic means a sharp drop in its stock price.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Editas Medicine Inc. (EDIT)
Editas Medicine is a pioneer in the revolutionary CRISPR genome editing technology. It's a clear bet on a scientific breakthrough. This chart measures the level of hope and fear. It shows when the stock is "overbought" on enthusiastic early trial data or "oversold" on safety concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Editas-Medicine-Inc.-EDIT&v=1772695663541 "RSI 14 indicator chart for the company's stock Editas Medicine Inc. (EDIT)")
RSI 14 Market Segment - Dna
Editas Medicine is a leading company in the field of genome editing. They use CRISPR technology (including their own variant of Cas12a) to develop drugs for rare genetic diseases. This chart measures the collective excitement in the gene therapy sector. It helps us understand whether the entire speculative segment is oversold.
RSI 14 for the overall market
Editas Medicine, a "genome editing" company, is pure R&D. This graph is its lifeline. During periods of euphoria, investors are willing to fund the "future of medicine." In moments of panic, they flee unprofitable biotech companies, and EDIT risks running out of funds for its breakthrough but expensive research.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast EDIT (Editas Medicine Inc.)
Editas Medicine is a leading CRISPR genome editing company developing treatments for genetic blood and eye diseases. This chart shows the average target price. Analysts' forecasts are based on clinical data demonstrating the efficacy and safety of their DNA editing method.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EDIT-Editas-Medicine-Inc.&v=1772695663620 "A chart showing analyst consensus forecasts for the expected stock price. EDIT (Editas Medicine Inc.)")
The difference between the consensus estimate and the actual stock price EDIT (Editas Medicine Inc.)
Editas Medicine (EDIT) is a pioneer in CRISPR gene editing. This is a pure R&D bet on their ability to treat genetic diseases. This chart shows the valuation of their science. It measures the gap between the price and the consensus target, reflecting the enormous (but speculative) potential analysts see in their ability to commercialize CRISPR.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EDIT-Editas-Medicine-Inc.&v=1772695663641 "A chart showing the difference between the consensus forecast and the actual stock price. EDIT (Editas Medicine Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Editas Medicine (EDIT) is a CRISPR pioneer. The company uses gene editing technology to create drugs for rare blood and eye diseases. This chart shows analysts' overall expectations for the DNA technology sector. It reflects whether experts believe CRISPR therapy will be commercialized.
Analysts' consensus forecast for the overall market share price
Editas Medicine is a leading genome editing company, pioneering the use of CRISPR technology to treat genetic diseases. This chart illustrates the overall "risk appetite." For Editas, operating at the very edge of science, overall market optimism (the rising chart) is essential for funding extremely expensive and time-consuming R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Editas Medicine Inc.
Editas Medicine (EDIT) is one of the pioneers and founders of the CRISPR gene editing industry. They develop drugs that can cut out or correct defective genes that cause diseases. This chart is a clear indicator of faith in their cutting-edge science. It reflects their progress in clinical trials (especially in eye and blood diseases) and their ability to compete in the CRISPR race.
AKIMA Market Segment Index - Dna
Editas Medicine is a leading genome editing company using CRISPR technology to treat genetic diseases. This chart shows the average index for the DNA technology segment. It allows investors to assess how Editas, at the forefront of science, outperforms or underperforms the sector average across a range of factors.
The AKIM Index for the overall market
Editas Medicine is a leading company in the field of CRISPR genome editing, developing treatments for serious genetic diseases. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this revolutionary technology.
